Open access
Oct 2026
Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study.
Not available.
Carl J. Rudebeck, L. Fornecker, B. Guffroy et al.
· Haematologica · 0 citations